SG11201902523UA - Anti-proliferative agents for treating pah - Google Patents
Anti-proliferative agents for treating pahInfo
- Publication number
- SG11201902523UA SG11201902523UA SG11201902523UA SG11201902523UA SG11201902523UA SG 11201902523U A SG11201902523U A SG 11201902523UA SG 11201902523U A SG11201902523U A SG 11201902523UA SG 11201902523U A SG11201902523U A SG 11201902523UA SG 11201902523U A SG11201902523U A SG 11201902523UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- new york
- pct
- applicant
- rule
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 2
- 108010081589 Becaplermin Proteins 0.000 abstract 1
- 101150012716 CDK1 gene Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 abstract 1
- 229960004390 palbociclib Drugs 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 01111111111111H 1101111111111011110111111 Organization International Bureau (10) International Publication Number 0 (43) International Publication Date ......0\" WO 2018/073687 Al 26 April 2018 (26.04.2018) WIP0 I PCT (51) International Patent Classification: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, A61K 31/519 (2006.01) A61P 11/00 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, A61K 45/06 (2006.01) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/IB2017/056226 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (22) International Filing Date: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 09 October 2017 (09.10.2017) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 62/410,566 20 October 2016 (20.10.2016) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 62/548,629 22 August 2017 (22.08.2017) US MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, KM, ML, MR, NE, SN, TD, TG). New York, New York 10017 (US). (72) Inventor: EVANS, Steven Martin; 7 Buehler Road, Bed- Declarations under Rule 4.17: ford, Massachusetts 01730 (US). — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) (74) Agent: WALDRON, Roy F. et al.; PFIZER INC., 235 East — as to the applicant's entitlement to claim the priority of the 42nd Street, MS 235/9/S20, New York, New York 10017 = earlier application (Rule 4.17(iii)) — (US). Published: (81) Designated States (unless otherwise indicated, for every — with international search report (Art. 21(3)) — kind of national protection available): AE, AG, AL, AM, — AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = = (54) Title: ANTI-PROLIFERATIVE AGENTS = = = _ = = 3.0 x10 6 =t = = — 2.0 x10 6 = n u..., \" 1-1 1.0 x10 6 .4 IN GC FOR TREATING PAH FIG. 1 Human PASMC a 30 ng/mL PDGF-BB ID Stimulation Window M IN 0 —.... 1-1 0 el (57) : Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by ad- ministering an effective dose of a CDK 1 1 -10 -8 Log[Palbo] M inhibitor, including palbociclib, 6- acetyl-8-cyclopenty1-5-methyl-2-{[5-(piperazin-1 - 0 yl)pyridin-2y1]amino}pyrido[2,3- d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410566P | 2016-10-20 | 2016-10-20 | |
| US201762548629P | 2017-08-22 | 2017-08-22 | |
| PCT/IB2017/056226 WO2018073687A1 (en) | 2016-10-20 | 2017-10-09 | Anti-proliferative agents for treating pah |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201902523UA true SG11201902523UA (en) | 2019-05-30 |
Family
ID=60138667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201902523UA SG11201902523UA (en) | 2016-10-20 | 2017-10-09 | Anti-proliferative agents for treating pah |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10849903B2 (en) |
| EP (2) | EP3528812B1 (en) |
| JP (2) | JP2018076290A (en) |
| KR (1) | KR20190071763A (en) |
| CN (1) | CN109843297A (en) |
| AU (1) | AU2017345367A1 (en) |
| BR (1) | BR112019005526A2 (en) |
| CA (1) | CA3040815C (en) |
| ES (2) | ES2934846T3 (en) |
| IL (1) | IL266026A (en) |
| MX (1) | MX2019004602A (en) |
| RU (1) | RU2019111887A (en) |
| SG (1) | SG11201902523UA (en) |
| TW (1) | TWI656876B (en) |
| WO (1) | WO2018073687A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021012491A (en) | 2019-04-19 | 2022-01-24 | Pfizer | Anti-proliferative agents for treating pah. |
| TWI769382B (en) * | 2019-06-21 | 2022-07-01 | 長庚大學 | Pharmaceutical composition and use for applying ribociclib in phosphodiesterase 4-mediated disease treatment of patient |
| CN112569357B (en) * | 2019-09-30 | 2023-03-28 | 深圳奥萨制药有限公司 | Composition of dual endothelin receptor antagonists and diuretic |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
| CA2407796A1 (en) | 2000-05-03 | 2001-11-08 | Hyun Ho Chung | Cdk inhibitors having 3-hydroxychromen-4-one structure |
| CN102295643B (en) | 2002-01-22 | 2013-12-04 | 沃尼尔·朗伯有限责任公司 | 2-(pyridin-2-ylamino)-pyrido[2,3d]pyrimidin-7-ones |
| TWI331034B (en) | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| SI1648889T1 (en) | 2003-07-11 | 2009-02-28 | Warner Lambert Co | Isethionate salt of a selective cdk4 inhibitor |
| ES2411975T3 (en) | 2005-01-14 | 2013-07-09 | Janssen Pharmaceutica Nv | 5-ring ringed heterocyclic pyrimidines as kinase inhibitors |
| TWI398252B (en) * | 2006-05-26 | 2013-06-11 | Novartis Ag | Pyrrolopyrimidine compounds and their uses |
| CA2662768A1 (en) | 2006-09-08 | 2008-03-20 | Pfizer Products Inc. | Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| JP5407865B2 (en) * | 2006-11-23 | 2014-02-05 | ジノクサ ファルマ ゲーエムベーハー | Pharmaceutical composition for treating capillary artery disease |
| WO2009047359A1 (en) * | 2007-10-12 | 2009-04-16 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| US8741861B2 (en) * | 2008-03-27 | 2014-06-03 | Vascular Biosciences | Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases |
| WO2010000913A1 (en) | 2008-07-04 | 2010-01-07 | Lauri Ilmari Pekansaari | Sauna oven center boiler |
| EP2303881A2 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| EP2716643A1 (en) | 2008-08-22 | 2014-04-09 | Novartis AG | Pyrrolopyrimidine compounds and their uses |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| IN2012DN01273A (en) | 2009-09-04 | 2015-05-15 | Novartis Ag | |
| EP2473499A1 (en) | 2009-09-04 | 2012-07-11 | Novartis AG | Bipyridines useful for the treatment of proliferative diseases |
| WO2011083387A1 (en) * | 2010-01-07 | 2011-07-14 | Pfizer Limited | Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester |
| UY33227A (en) | 2010-02-19 | 2011-09-30 | Novartis Ag | PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6 |
| RS55135B1 (en) | 2010-10-25 | 2016-12-30 | G1 Therapeutics Inc | Cdk inhibitors |
| BR112013012313A2 (en) | 2010-11-19 | 2019-09-24 | Piramal Entpr Ltd | paclitaxel pharmaceutical combination and a cdk inhibitor |
| PL3431475T3 (en) | 2013-02-21 | 2021-09-13 | Pfizer Inc. | Solid forms of a selective cdk4/6 inhibitor |
| JP6605493B2 (en) * | 2014-04-11 | 2019-11-13 | バイエル ファーマ アクチエンゲゼルシャフト | New macrocyclic compounds |
| US9828373B2 (en) | 2014-07-26 | 2017-11-28 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof |
| CN105294655B (en) | 2014-07-26 | 2019-03-15 | 广东东阳光药业有限公司 | The compound and application thereof of CDK type small molecular inhibitor |
| WO2016053040A1 (en) | 2014-10-02 | 2016-04-07 | 주식회사 엘지화학 | Electrolyte additive for lithium secondary battery and non-aqueous electrolyte and lithium secondary battery comprising the electrolyte additive |
| CN104758292B (en) * | 2015-03-06 | 2018-05-01 | 天津医科大学总医院 | PD-0332991 is preparing the purposes of prevention drug-resistant tumor drug |
| US10822337B2 (en) * | 2015-04-01 | 2020-11-03 | Rigel Pharmaceuticals, Inc. | TGF-β inhibitorC |
-
2017
- 2017-10-09 CA CA3040815A patent/CA3040815C/en active Active
- 2017-10-09 ES ES20203847T patent/ES2934846T3/en active Active
- 2017-10-09 MX MX2019004602A patent/MX2019004602A/en unknown
- 2017-10-09 AU AU2017345367A patent/AU2017345367A1/en not_active Abandoned
- 2017-10-09 WO PCT/IB2017/056226 patent/WO2018073687A1/en unknown
- 2017-10-09 EP EP17787029.2A patent/EP3528812B1/en active Active
- 2017-10-09 CN CN201780064690.9A patent/CN109843297A/en active Pending
- 2017-10-09 RU RU2019111887A patent/RU2019111887A/en not_active Application Discontinuation
- 2017-10-09 BR BR112019005526A patent/BR112019005526A2/en not_active Application Discontinuation
- 2017-10-09 KR KR1020197014211A patent/KR20190071763A/en not_active Application Discontinuation
- 2017-10-09 ES ES17787029T patent/ES2852349T3/en active Active
- 2017-10-09 US US16/343,566 patent/US10849903B2/en active Active
- 2017-10-09 EP EP20203847.7A patent/EP3804724B1/en active Active
- 2017-10-09 SG SG11201902523UA patent/SG11201902523UA/en unknown
- 2017-10-17 TW TW106135422A patent/TWI656876B/en not_active IP Right Cessation
- 2017-10-18 JP JP2017201576A patent/JP2018076290A/en active Pending
-
2019
- 2019-04-14 IL IL266026A patent/IL266026A/en unknown
-
2020
- 2020-11-04 US US17/089,154 patent/US11439646B2/en active Active
- 2020-12-01 JP JP2020199659A patent/JP2021038265A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018076290A (en) | 2018-05-17 |
| CN109843297A (en) | 2019-06-04 |
| AU2017345367A1 (en) | 2019-04-04 |
| EP3528812A1 (en) | 2019-08-28 |
| CA3040815A1 (en) | 2018-04-26 |
| BR112019005526A2 (en) | 2019-06-18 |
| ES2852349T3 (en) | 2021-09-13 |
| TW201827054A (en) | 2018-08-01 |
| EP3528812B1 (en) | 2020-12-30 |
| US20190240226A1 (en) | 2019-08-08 |
| JP2021038265A (en) | 2021-03-11 |
| US11439646B2 (en) | 2022-09-13 |
| EP3804724B1 (en) | 2022-12-07 |
| EP3804724A1 (en) | 2021-04-14 |
| MX2019004602A (en) | 2019-06-17 |
| RU2019111887A3 (en) | 2020-11-20 |
| IL266026A (en) | 2019-06-30 |
| TWI656876B (en) | 2019-04-21 |
| US20210186974A1 (en) | 2021-06-24 |
| ES2934846T3 (en) | 2023-02-27 |
| CA3040815C (en) | 2021-07-20 |
| WO2018073687A1 (en) | 2018-04-26 |
| KR20190071763A (en) | 2019-06-24 |
| US10849903B2 (en) | 2020-12-01 |
| RU2019111887A (en) | 2020-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201903155XA (en) | Pharmaceutical compounds | |
| SG11201805872SA (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201807965YA (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
| SG11201810793XA (en) | Pharmaceutical combinations | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer | |
| SG11201809788VA (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer |